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evaluated by 2 independent, trained research assistants who were blinded to the test results. 48
Comparative evaluations of diagnostic performance for AN were made at preset 49 manufacturers´ thresholds (range: 2.0-17.0µg Hb/g feces), at a uniform threshold (15 µg 50 Hb/g feces), and at adjusted thresholds yielding defined levels of specificity (99%, 97%, and 51
93%). 52 53
Results: Of the 1667 participants who fulfilled the inclusion criteria, all cases with AN 54 (n=216) and 300 randomly selected individuals without AN were included in the analysis. 55
Sensitivities and specificities for AN varied widely when we used the preset thresholds 56 (21.8%-46.3% and 85.7%-97.7%, respectively) or the uniform threshold (16.2%-34.3% and 57 94.0%-98.0%, respectively). Adjusting thresholds to yield a specificity of 99%, 97%, or 93% 58 resulted in almost equal sensitivities for detection of AN (14.4%-18.5%, 21.3%-23.6%, and 59 30.1%-35.2%, respectively) and almost equal positivity rates (2.8%-3.4%, 5.8%-6.1% and 60
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INTRODUCTION 71
Colorectal cancer (CRC) is the third most common cancer globally, accounting for 72 approximately 1.4 million new cases and 700,000 deaths per year.
1 Randomized controlled 73 trials have shown that annual or biannual screening with traditional, guaiac-based fecal 74 occult blood tests could reduce CRC mortality by up to 30%. [2] [3] [4] Even stronger mortality 75 reduction should be possible with newer fecal immunochemical tests (FITs) for hemoglobin 76 (Hb), which have been shown to have substantially higher sensitivity, not only to detect CRC, 77 but also its most important precursor, advanced adenoma (AA). [5] [6] [7] Therefore, FITs are 78 meanwhile widely recommended as primary CRC screening tests 8, 9 and used as such in an 79 increasing number of countries. 10 With the growing market for FIT-based screening, a large 80 number of FITs from diverse manufacturers are meanwhile being offered. Although 81 diagnostic performance of specific FIT brands has been evaluated in previous studies, 11, 12 82 the heterogeneity of study designs, study populations, pre-analytical sample handling, and 83 positivity thresholds makes a comparative evaluation of the diagnostic performance of 84 different FIT brands difficult if not impossible. Only very few studies have evaluated more 85 than one FIT based on the same stool samples. In a previous study, we evaluated diagnostic 86 performance of six different qualitative point of care FITs in a cohort of participants of 87 screening colonoscopy in Germany.
13 A large diversity of sensitivities and specificities was 88 The aim of this study was to evaluate and directly compare diagnostic performance of nine 93 different quantitative commercially available and clinically used FITs, including both 94 laboratory-based FITs as well as point of care FITs, based on the same stool samples 95 collected from our large cohort of participants of screening colonoscopy. 96 M A N U S C R I P T ancillary analyses who were recruited in the DACHSplus satellite sub-study of the DACHS 110 (DArmkrebs: CHancen der Verhütung durch Screening) study, a case-control study with a 111 focus on the role of colonoscopy in CRC prevention. In the DACHSplus sub-study cancer 112 patients were referred by general practitioners or gastroenterologists for surgery to one of 113 four collaborating hospitals, where the patients were informed about the study and recruited 114 prior to initiation of any therapy. 115
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MATERIALS AND METHODS 97
Further information on both, BliTz and DACHSplus has been provided elsewhere. 7, 13, 16, 17 116 Both studies were approved by the Ethics committee of the University of Heidelberg and by 117 the State Chambers of Phyiscians of Baden-Wuerttemberg, Rhineland-Palatinate and Hesse. 118
Between 2005 and 2010, participants from BliTz and DACHSplus received a study kit which 119 included a stool collection container (60ml). These individuals were considered for this 120 project. Figure 1 shows the exclusion criteria and flow diagrams of the study participants. Briefly, 566 122 samples were analyzed in total. From the main study, conducted in the screening setting 123 (BliTz study), all eligible advanced neoplasm (AN)-cases (n=216) were included (i.e., cases 124 with CRC or AA, defined as adenoma with at least one of the following features: ≥1cm in 125 size, tubulovillous or villous components, or high-grade dysplasia). The 300 participants 126 without AN (including participants with non-advanced adenomas, hyperplastic polyps and no 127 neoplasms) were randomly selected from all eligible participants (n=1437) in this group. Due 128 to the low number of CRC cases which is typical of true screening settings, 50 CRC cases 129 from the DACHSplus study (clinical setting) were additionally included for ancillary analyses. 130
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Sample and data collection 131
After giving written informed consent, participants were asked to collect one stool sample 132 from a single bowel movement, without any specific recommendations for dietary or 133 medicinal restrictions, before bowel preparation for colonoscopy (screening setting) or 134 surgery (clinical setting). Participants were furthermore asked to keep the stool-filled 135 container in a freezer or, if not possible, in a refrigerator at home until their colonoscopy 136 appointment (screening setting) or hospital admission (clinical setting). Upon receipt the 137 stool-filled containers were immediately frozen at -20°C in the practice (screening setting) or 138 in the hospital (clinical setting), then shipped on dry ice to a central laboratory and finally 139 stored at -80°C at the German Cancer Research Cente r (DKFZ) study center. 140
In addition, participants were asked to fill out a questionnaire focusing on CRC risk factors. 141
Colonoscopy and histology reports were collected from all participants of the screening 142 colonoscopy. Colonoscopists were blinded for test results. After surgery, medical reports on 143 the clinical patients were collected from the hospital. Relevant information was extracted by 144 two independent trained research assistants who were blinded to the test results.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
For the purpose of this evaluation, which was conducted in fall 2016, the stool samples were 147 thawed overnight in a refrigerator at the study center and homogenized with a sterile plastic 148 stick. A defined stool amount was extracted in a randomized order using each company's 149 brand-specific fecal sampling device (FSD). Each FSD was a small vial, containing a defined 150 volume of Hb-stabilizing buffer, with a lid that was attached to a serrated plastic stick for stool 151 collection. After stabbing the collection stick into three different parts of the stool sample, we 152 checked if all serrations on the stick were filled completely. Then we inserted the stick with 153 the collected stool back into the vial. The vials have a tight membrane at their entrance which 154 removes most of the stool, leaving only a specified quantitative amount of stool in the 155 serrations even though this may not be consistently successful in practice. The only 156 exception was the ImmoCare-C vial, where a supplied custom-fitted scraper was used to 157 remove excess stool material from the collection stick. All FSDs were subsequently mixed on 158 a vortexer, so that the stool could move out of the serrations into the buffer. FITs; one of the latter (QuantOn Hem) would not even require a local analytical instrument, 172 but could be run with remote testing using a smartphone with an App for optical analysis of 173 the test cassette.
Statistical analyses 175
Sensitivities were calculated for CRC, AA, and their combination, AN, with their 176 corresponding 95% confidence interval (CI) at preset manufacturers´ thresholds and at 177 adjusted thresholds, using colonoscopy results as the reference standard. Specificities were 178 calculated for the absence of any AN. The Clopper-Pearson method was used to calculate 179 95% CIs. The expected positivity rate of the tests in a true screening setting was calculated 180 by applying the observed sensitivity and specificity to all eligible participants with and without 181
ANs from the screening setting (n=230 and n=1437, respectively), using the following 182
formula: 183
Expected positivity rate = (Sensitivity*230 + (1-Specificity)*1437)/(230+1437). 184
In order to evaluate the diagnostic performance of the tests across different thresholds, 185 receiver operating characteristic (ROC) curves were constructed and the areas under the 186 curves (AUCs) were determined. Because of the low number of CRC cases in the screening 187 setting and the similarity of sensitivities for CRC cases in the screening and the clinical 188 setting, the ROC plot for CRC was constructed combining both groups of cases. The ROC 189 analysis for AN on the other hand is purely based on the screening setting. 190
In addition to analyses for both sexes combined, sex specific analyses were performed. For 191 CRC cases, stage specific sensitivities were evaluated in addition to overall sensitivities. setting, stage specific analyses were performed for both groups combined. 197
All statistical analyses were conducted using SAS Enterprise Guide, version 6.1 (SAS 198 Institute, Cary, North Carolina, USA). From the DACHSplus study (clinical setting) (Figure 1, B) , a total of 184 CRC cases 213 provided stool-filled containers. After exclusion of participants with neoadjuvant therapy 214 before stool sampling (n=51), age <50 or ≥80 years (n=30), inflammatory bowel disease 215 (n=3) or personal history of CRC (n=6), 94 individuals with CRC were eligible for this study. 216
All patients diagnosed through a screening colonoscopy and supplying a sufficient stool 217 amount (n=27) were included. From the 65 patients whose CRC was detected otherwise (i.e. 218 not by screening colonoscopy) 23 individuals were randomly selected for this study. Finally, 219 50 clinical CRC cases were included for the ancillary analyses. 220
An overview on basic characteristics of the study participants is provided in Table 2 . A slight 221 majority of participants in both the main study (screening setting) and the ancillary study 222 (clinical setting) were males, mean ages were 63.2 and 65.8 years, respectively. The 223 majority of CRC cases from both the screening setting (9/16) and the clinical setting (30/50) 224 were diagnosed at an early stage (0/I/II). 225 M A N U S C R I P T At preset thresholds the sensitivities (95% CI) for AN ranged from 21.8% (16%-28%) to 230 46.3% (40%-53%), with corresponding specificities (95% CI) between 97.7% (95%-99%) 231 and 85.7% (81%-89%) (upper part of Table 3 ). This apparent strong variation in sensitivity 232
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Comparison of test characteristics 226
and specificity seemed to be determined to a large extent by the variation of preset 233 thresholds, with sensitivity strongly decreasing and specificity increasing with increasing 234 thresholds. The sensitivities for AN were mostly determined by the sensitivities for AA, which 235 make up the vast majority of AN in screening settings. Sensitivities for AA ranged from 236 18.0% to 43.5%, whereas much higher sensitivities, ranging from 62.5% to 81.3%, were 237 observed for CRC. Using the thresholds preset by the manufacturers also yielded strongly 238 varying expected positivity rates, ranging from 5.7% to 18.7%, when applying the tests in a 239 true screening setting. 240
By adjusting the thresholds to yield the same levels of specificity for all tests the 241 heterogeneity in the sensitivities and the expected positivity rates were substantially reduced 242 or disappeared almost entirely (Table 4) . With thresholds yielding a specificity of 99.0%, 243 sensitivities (95% CI) for AN ranged from 14.4% (10%-20%) to 18.5% (14%-24%), and 244 expected positivity rates ranged from 2.8% to 3.4%. For one test (RIDASCREEN Hb), the 245 threshold could not be increased above the upper analytical range (50 µg Hb/g feces) to yield 246 a specificity of 99%. With thresholds yielding a specificity of 96.7%, sensitivities (95% CI) for 247 AN ranged from 21.3% (16%-27%) to 23.6% (18%-30%), and expected positivity rates 248 ranged from 5.8% to 6.1%. With thresholds yielding a specificity of 93.0%, the sensitivities 249 (95% CI) for AN ranged from 30.1% (24%-36%) to 35.2% (29%-42%), and the expected 250 positivity rates ranged from 10.1% to 10.9%. For one test (QuikRead go iFOBT), the 251 threshold could not be lowered to yield a specificity of 93%, because of the limited analytical 252 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT range (lower limit 15 µg Hb/g feces). For one other test (SENTiFIT-FOB Gold) the specificity 253 of 93.3% was achieved at the lower end of its analytical range. 254
However, identical levels of specificities and very similar levels of sensitivities and expected 255 positivity rates were achieved at apparently very different thresholds. Thresholds [µg Hb/g 256 feces] that yielded specificities of 99.0%, 96.7% and 93.0% ranged from 18.20 to 53.38, from 257 6.11 to 29.54 and from 1.70 to 12.27, respectively. Vice versa, using a uniform threshold 258 (here: 15 µg Hb/g feces, the lower end of the analytical range of one of the tests) resulted in 259 strongly varying sensitivities (range of sensitivities for AN: 16.2% to 34.3%) and expected 260 positivity rates (3.4% to 9.9%) (lower part of Table 3) . 261
Overall, the sensitivities for CRC cases recruited in the screening setting and for CRC cases 262 recruited in the clinical setting were very similar, but CIs were much narrower for the latter 263 due to the substantially larger case number. When investigating the sensitivities according to 264 CRC stage, sensitivities were higher for late (III/IV) stages versus early (0/I/II) stages for 265 eight of the nine tests, with a median difference of 9 percent units ( Table 5) . 266 AUCs (95% CI) for CRC ranged from 79% (73%-85%) to 89% (84%-94%). For the detection 269 of AN, the AUCs (95% CI) ranged from 59% (57%-62%) to 72% (68%-77%). Most of the 270 apparent differences in ROC curves and AUCs resulted from the varying limits of the tests' 271 analytical range, with ROC curves going either straight to the upper-right or to the lower-left 272 corner for thresholds below or above the analytical range, respectively. Therefore no 273 statistical tests for differences between the AUCs were performed. Segments of the ROC 274 curves not affected by the limits of the analytical range were generally very close. 275
In sex specific analyses sensitivity was consistently higher and specificity was consistently 276 lower among men than among women at the same thresholds, but ROC curves and AUCs 277 were essentially identical. 278
To our knowledge, this is the first comprehensive comparative evaluation of diagnostic 280 performance of a large number of quantitative FITs in a screening setting. Apparent large 281 differences in diagnostic performance parameters were seen when using either preset 282 thresholds recommended by the manufacturers or a uniform threshold. However, these 283 apparent large differences almost entirely disappeared when thresholds were adjusted in 284 such a way that all tests achieved defined levels of specificity (here: 99.0%, 96.7% and 285 93.0%), at which sensitivities were also all very close. Along the same lines, ROC curves and 286
AUCs were all very similar except for some variation due to differences in the lower or upper 287 end of the analytical range. 288
In a previous study from our group, similarly large apparent differences in diagnostic 289 performance had been found for six different qualitative FITs. 13 Like in the present study, 290
qualitative FITs with higher sensitivities had shown lower specificities and vice versa, 291 pointing to differences in the threshold definition. However, due to the qualitative nature of 292 the tests, no further exploration of the impact of shifting thresholds had been possible. 293
Quantitative tests offer the advantage of flexible definition of thresholds. Such flexibility can 294 be very useful to enable the best balance between sensitivity and specificity or to adapt 295 positivity rates (which are close to 1 minus specificity in screening settings in which 296 prevalence of AN is low) to colonoscopy capacities available for the screening population. 297
Further advantages include the possibility of automated, objective measurements under 298 quality controlled laboratory conditions. 299
Although a large number of studies have meanwhile evaluated the diagnostic performance of 300 single quantitative FITs, 11, 12, 16, [19] [20] [21] [22] and results even have been combined in meta-301 analyses, 11 only very few studies have evaluated more than one quantitative FIT in the same 302 study population. It was therefore essentially unknown to what extent the reported partly very 303 large differences in sensitivity and specificity might have resulted from true differences in 304 diagnostic performance of the tests, or from differences in the populations studied or otherM A N U S C R I P T
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specific study characteristics, such as collection and pre-analytical handling of fecal samples. 306
To our knowledge, only two studies from our group directly compared the diagnostic 307 performance of two quantitative FITs (OC Sensor and RIDASCREEN Hb) among participants 308 of screening colonoscopy, evaluating identical stool samples.
7, 17 Similar diagnostic 309 performance of the two quantitative FITs was observed when the thresholds were adjusted to 310 yield the same overall positivity rate (5%) 7 or the same specificity levels (90% and 95%). 
320
The design of our study essentially precluded any differences in study populations or sample 321 handling as a cause of differences in observed diagnostic performance: All tests were 322 evaluated in exactly the same study participants who were recruited in a true screening 323 setting among participants of screening colonoscopy. Stool samples were collected in exactly 324 the same manner, and additional homogenization of stool samples after thawing and before 325 stool extraction for the single tests should further have eliminated the variation of Hb 326 concentrations within a single bowel movement. Under these precautions, all nine tests 327 included were shown to perform essentially equally well overall, with the remaining, apparent 328 heterogeneity being almost exclusively threshold-related. However, in agreement with the 329 findings from Chiang et al 23 , our results illustrate that the threshold-related heterogeneity 330 cannot simply be overcome by using the same threshold across different quantitative FIT 331 brands. The most plausible reason for that seems to be variation in the "translation" of tests 332 M A N U S C R I P T
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14 results into Hb concentrations given by the manufacturers for the various tests. While the 333 reasons for such variation cannot be disclosed by our study, our results underline the need of 334 enhanced efforts for standardization and quality control. Interestingly, setting the thresholds 335 to ensure defined levels of specificity (which is independent of such "translation") ensured 336 levels of sensitivity to be quite similar as well. 337
In practice, determining test specificity or defining a threshold according to specificity in the 338 context of an established FIT-based screening program is often difficult, as typically only FIT 339 positive participants would undergo colonoscopy. However, choosing a threshold to ensure a 340 defined positivity rate is straightforward. With AN as the major outcome, which typically has a 341 prevalence of less than 10% in screening populations, the positivity rate is closely related to 342 specificity (it is typically a few percentage points higher than one minus specificity). For 343 example, thresholds yielding specificities of 99.0%, 96.7% and 93.0% in our study resulted in 344 very narrow ranges of positivity rates from 2.8% to 3.4%, from 5.8% to 6.1% and from 10.1% 345 to 10.9%, respectively. Vice versa, adjusting the threshold to defined levels of the positivity 346 rate would have resulted in very narrow ranges of specificities across tests (data not shown). 347
An additional advantage of choosing thresholds according to a defined positivity rate would 348 be that the latter directly reflects the colonoscopy workload associated with the FIT-based 349 screening program, which is a limiting factor in many countries. 350
Given that diagnostic performance of the various tests evaluated in our study was very 351 similar after threshold adjustments, additional factors might determine advantages and 352 disadvantages of the different tests. One obvious factor directly evident from our analyses is 353 the width of the analytical range which delineates possibilities of threshold adjustment. Other 354 factors to be considered which are beyond the scope of our study, might be, for example, 355 costs of tests, convenience of sample collection, sample stability under routine environmental 356 conditions, laboratory requirements, and ease of laboratory analysis. Interestingly, apart from 357 the high lower end of the analytical range of one of the point of care tests, no consistent 358 differences in diagnostic performance were seen between laboratory-based and point of care 359 M A N U S C R I P T
tests, and equivalent diagnostic performance was even achieved with a smartphone-based 360 test that could be conducted by the participants at their home without the need of any sample 361 shipment, suggesting interesting perspectives for novel telemedicine applications. 362
Nevertheless, the possibility should be kept in mind that diagnostic performance of point of 363 care tests might be somewhat lower when these tests are applied in routine medical practice. 364
Specific strengths of our study include the first time parallel evaluation of a large number of 365 quantitative FITs in a screening setting, with screening colonoscopy results as reference in 366 all participants. However, our study also has a number of limitations that require careful 367 discussion. First, stool samples were originally collected in small containers rather than FSDs 368 provided by the manufacturers and stored frozen at -80°C over several years prior to 369
analysis. This was though probably the only way to realize a comparative study like this, as it 370 is difficult to imagine that study participants would be willing to collect nine fecal samples with 371 nine different FSDs, each with different sample collection instructions. Nevertheless, the 372 original FSDs provided by the manufacturers were used when extracting the fecal samples 373 from the thawed stool, and prior homogenization of the thawed stool ruled out variation of Hb 374 concentration within the same bowel movement as an additional source of variation of results 375 between tests (even though this might lead to somewhat better diagnostic performance 376 compared to routine practice where such homogenization is not performed). In a previous 377 examination based on one of the tests included in the current study (SENTiFIT-FOB Gold), 378
we furthermore found only small differences in comparative analyses of the diagnostic 379 performance based on frozen fecal samples or fecal samples collected according to the 380 manufacturer's instructions. 16 Similarly, two of the tests (OC Sensor and RIDASCREEN Hb) 381 which had been evaluated in an overlapping selection of the same fecal samples (with one 382 less freeze-thaw cycle, and without prior homogenization) several years earlier, 7, 17 showed 383 very similar results in the overlapping segments of the study populations (data not shown). 384
Second, despite the overall large size of the study, with targeted selection of samples 385 (including those from all CRC cases) from more than 1600 participants of screening 386 colonoscopy, the number of CRC cases from the screening setting was still rather lowM A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT (n=16), leading to broad CIs for the sensitivity estimates for CRC. More precise estimates 388 were possible, however, by additionally considering CRC cases from our ancillary study from 389 the clinical setting (of whom approximately half also had screen-detected CRC). Given the 390 similarity of sensitivity estimates for CRC cases recruited in the screening setting and in the 391 clinical setting for all of the nine tests evaluated, combining the analyses for both groups of 392 CRC patients seems justified. 393
Despite its limitations, our study provides important information regarding the diagnostic 394 performance and its comparability for a large number of quantitative FITs including 395 quantitative FITs that are now widely used in screening practice, such as SENTiFIT-FOB 396
Gold, the test used in the nationwide screening program in the Netherlands. With appropriate 397 threshold adjustments all of the tests included in our evaluation seemed to perform almost 398 equally well. Therefore additional criteria, such as costs, convenience of sample collection 399 and analysis, or stability of results over prolonged sample storing or shipping times, to be 400 evaluated in further, similarly highly standardized comparative investigations, as well as the 401 analytical range may be relevant when selecting one or more quantitative FIT brands for 402 specific screening programs. Furthermore, rather than simply using thresholds 403 recommended by the manufacturer, screening programs should choose thresholds based on 404 intended levels of specificity and manageable positivity rates. FIT=Fecal immunochemical test; Hb=Hemoglobin; App=mobile application software; iOS=iPhone operating system; *iPhone 6s was used for this study. 
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